• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Amylyx Pharmaceuticals, Inc. - Common Stock (NQ: AMLX )

    3.785 -0.285 (-7.00%)
    Streaming Delayed Price Updated: 2:23 PM EST, Dec 27, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 420,364
    Open 4.010
    Bid (Size) 3.780 (5)
    Ask (Size) 3.790 (8)
    Prev. Close 4.070
    Today's Range 3.755 - 4.080
    52wk Range 1.575 - 19.95
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    4 Analysts Assess Amylyx Pharma: What You Need To Know
    Via Benzinga
    Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire

    Performance

    YTD
    -74.72%
    -74.72%
    1 Month
    -30.55%
    -30.55%
    3 Month
    +18.28%
    +18.28%
    6 Month
    +96.11%
    +96.11%
    1 Year
    -73.97%
    -73.97%

    More News

    Read More
    Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    Analyst Ratings For Amylyx Pharma
    Via Benzinga
    6 Analysts Assess Amylyx Pharma: What You Need To Know
    Via Benzinga
    Breaking Down Amylyx Pharma: 9 Analysts Share Their Views
    Via Benzinga
    Crude Oil Rises Sharply; US Homebuilder Sentiment Surges In November
    Via Benzinga
    Exposures Fossil Fuels
    Twist Bioscience Posts Upbeat Results, Joins Tesla, Amylyx Pharmaceuticals, Regenxbio And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    This Robinhood Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
    Via Benzinga
    Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    Why Amylyx Pharmaceuticals Stock Was So Healthy This Week
    Via The Motley Fool
    Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    Reneo Pharmaceuticals And 2 Other Stocks Under $5 Executives Are Buying
    Via Benzinga
    Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer’s Disease Pathology and Neurodegeneration
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    Amylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    Amylyx Pharmaceuticals Receives Orphan Drug Designation From the European Commission for AMX0035 for the Treatment of Wolfram Syndrome
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    NVIDIA To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Friday
    Via Benzinga
    Why Is Small Cap Amylyx Pharmaceuticals Stock Trading Higher On Wednesday?
    Via Benzinga
    Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of Avexitide
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.